Advertisement

Advertisement
Alicia K. Morgans, MD, MPH, and Ian D. Davis, PhD, MBBS, on Prostate Cancer: Updated Overall Survival Outcomes With Enzalutamide

Alicia K. Morgans, MD, MPH, and Ian D. Davis, PhD, MBBS, on Prostate Cancer: Updated Overall Survival Outcomes With Enzalutamide

Rates of Active Surveillance Rising Among Men With Low-Risk Prostate Cancer but Still Suboptimal

Most men with low-risk prostate tumors now opt for active surveillance, but overtreatment remains a problem, according to data presented during the 2022 American Urological Association (AUA) Annual Meeting. A retrospective analysis of more than 20,000 patients with low-risk prostate cancer showed that approximately 60% of men who were eligible for active surveillance chose that approach in 2021, up from 27% in 2014. Authors of the study noted, however, that treatment rates among men with low-risk prostate tumors remain suboptimal, with wide variation across providers.

Potential Association of the 2012 USPSTF Grade D Recommendation Against PSA Screening With Changes in Prostate Cancer–Specific Mortality

In a study reported in JAMA Network Open, Burgess et al found that the 2012 U.S. Preventive Services Task Force (USPSTF) Grade D recommendation against prostate-specific antigen (PSA) screening for all men appeared to be associated with ending of a trend of annual reductions in prostate cancer–specific mortality. 

Differences in Germline Variant Spectrum Between Black and White Men With Prostate Cancer

Differences in Germline Variant Spectrum Between Black and White Men With Prostate Cancer

In a study presented at the 2022 ASCO Annual Meeting and simultaneously published in JCO Precision Oncology, Veda N. Giri, MD, and colleagues found that Black men with prostate cancer exhibited a lower frequency and narrower spectrum of germline pathogenic or likely pathogenic variants and a higher frequency of variants of unknown significance vs White men, including multiple variants of unknown significance in DNA repair genes.

Does Treatment With 5α-Reductase Inhibitors Impact the Risk of Dying of Prostate Cancer Among Men Without a Prior Diagnosis of the Disease?

In a Swedish study reported in JAMA Oncology, Björnebo et al found that longer use of 5α-reductase inhibitors for the treatment of benign prostatic hyperplasia was associated with a reduced risk of prostate cancer mortality among men without a prior diagnosis of prostate cancer.

Adverse Events Seen With Abiraterone or Enzalutamide Among Patients With Advanced Prostate Cancer

Men taking either of the two most common oral medications for advanced prostate cancer who had also undergone hormone therapy to treat their disease were at higher risk of serious metabolic or cardiovascular issues than patients who were receiving hormone therapy alone, according to findings published by Lai et al in the Journal of the National Cancer Institute.

Advertisement


Advertisement